Viral and non-viral vectors in gene therapy: Technology development and clinical trials

被引：81

作者：

Lundstrom, K ^{[1
]}

Boulikas, T

机构：

[1] Regulon Inc, BioXtal, CH-1066 Epalinges, Switzerland

[2] Regulon Inc, Mountain View, CA USA

来源：

TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2003年 / 2卷 / 05期

关键词：

D O I：

10.1177/153303460300200513

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gene therapy as part of modern molecular medicine holds great promise for the treatment of both acute and chronic diseases and has the potential to bring a revolutionary era to cancer treatment. Gene therapy has been named the medicine of the future. For the past 10 years various viral and non-viral vectors have been engineered for improved gene and drug delivery. Although various diseases have been targeted, cancer therapy has been addressed to a large extent because of the straight forward approach. Delivery of toxic or immunostimulatory genes by viral and non-viral vectors has been investigated and encouraging results have been obtained in animal models. A large number of clinical trials have been conducted with some highly promising outcome. We propose that combinations of viruses with liposomes or polymers will solve the problem of systemic viral delivery and tumor targeting, bringing a revolution in molecular medicine and in applications of gene therapy in humans.

引用

页码：471 / 485

页数：15

共 103 条

[1] Endovascular microcoil gene delivery using immobilized anti-adenovirus antibody for vector tethering [J].